BIORESTORAT.THERAP.DL-01
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more
BIORESTORAT.THERAP.DL-01 (9OF) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIORESTORAT.THERAP.DL-01 (9OF) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIORESTORAT.THERAP.DL-01 - Net Assets Trend (None–None)
This chart illustrates how BIORESTORAT.THERAP.DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIORESTORAT.THERAP.DL-01 (None–None)
The table below shows the annual net assets of BIORESTORAT.THERAP.DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIORESTORAT.THERAP.DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIORESTORAT.THERAP.DL-01 Competitors by Market Cap
The table below lists competitors of BIORESTORAT.THERAP.DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bryah Resources Ltd
AU:BYH
|
$1.42 Million |
|
Antarctica Limited
NSE:ANTGRAPHIC
|
$1.42 Million |
|
Anoto Group AB (publ)
OTCGREY:AOTOF
|
$1.42 Million |
|
Trugolf Inc
NASDAQ:TRUG
|
$1.42 Million |
|
TOTALENERGIES MARKETING MAROC
BC:TOTALENERGIES-MARKETING-MAROC
|
$1.41 Million |
|
Madhav Marbles and Granites Limited
NSE:MADHAV
|
$1.41 Million |
|
286 Lenox Partners LLC
OTCGREY:TESLU
|
$1.41 Million |
|
Creepy Jar S.A.
F:3CJ
|
$1.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIORESTORAT.THERAP.DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIORESTORAT.THERAP.DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIORESTORAT.THERAP.DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIORESTORAT.THERAP.DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIORESTORAT.THERAP.DL-01 (9OF) | €- | N/A | N/A | $1.42 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |